Gilead, a research-based biopharmaceutical company, completed the acquisition of Forty Seven, a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways, for $4.9bn. “We will now work together to accelerate the progress of magrolimab and advance Gilead’s work in immuno-oncology. I am delighted to welcome the Forty Seven team, whose unique expertise will be of great value as we grow our clinical pipeline and work to help more patients with some of the toughest forms of cancer,” Daniel O’Day, Gilead Sciences Chairman and Chief Executive Officer.